Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine
Award Recognizes Achievements in Cancer Immunotherapy
“We are especially proud to have Jim recognized for his transformational contribution to science and to patients battling cancer. His advances in the field of immunotherapy are fundamentally changing the way doctors manage cancer treatment,” said Hugh O’Dowd, president and chief executive officer of
Dr. Allison is professor and chair of The
“This is a well-deserved honor, and the entire
About
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.
For more information, please visit www.neontherapeutics.com.
Media Contact:
stephanie@tenbridgecommunications.com
617-581-9333
Investor Contact:
Will O’Connor, Stern Investor Relations
will@sternir.com
212-362-1200
Source: Neon Therapeutics, Inc.